Topic:

Regulatory

Latest Headlines

Latest Headlines

Pakistan's new drug pricing policy to cut some costs by one-third

Pakistan's minister in charge of drug pricing confirmed at a news conference a new policy would reduce the costs of some drugs by as much as 30%, but said no changes would become effective before June 30, 2016.

Indian regulator places 5-year ban on Kivi Labs for forgery

India authorities placed a 5-year ban on Kivi Labs for submitting any filings with the Central Drugs Standards Control Organization after determining the company filed fictitious and forged documents for fixed-dosage combinations.

India threatens to close pharmacies that fail to stock adequate Tamiflu

India health authorities have threatened to close pharmacies in the country that fail to maintain an adequate supply of Tamiflu (oseltamivir) or its generics to treat an outbreak of H1N1 influenza.

India mulling plans to build bulk drug manufacturing capacity

The Indian government is expected to announce new strategies to bolster its bulk drug manufacturing capacity as part of an effort to reduce the country's dependency on Chinese API imports.

The Apple Watch won't keep the doctor away: Advanced health features get cut prior to launch

"One of the biggest surprises people are going to have when they start using it is the breadth of what it will do," Apple CEO Tim Cook recently said about the upcoming Apple Watch. Too bad the smartwatch's functionalities won't include stress monitors, an electrocardiogram or a blood pressure monitor.

Pharma wanted pricey orphan meds, and now it's got 'em in record numbers

New drug approvals were up last year, and orphan drug approvals were no exception. But by just how much did they climb? The  FDA Law Blog  has done some digging through the agency's Orphan Drug Designations and Approvals database, and it's got an answer.

Apotex targets Amgen's blockbuster with latest biosimilar app

The FDA accepted Apotex's application to copy an Amgen blockbuster, giving the Canadian drugmaker a chance to cash in on the coming biosimilar boom in the U.S.

UPDATED: FDA agrees to review Pfizer's abuse-deterring opioid candidate

Pharma bigwig Pfizer announced that the FDA has agreed to review the New Drug Application of its abuse-deterring extended-release opioid capsules, dubbed ALO-02.

Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object

Eisai won speedy FDA approval for its new cancer drug Lenvima, eyeing $1 billion in potential sales and setting the stage for a showdown with Bayer's cancer-fighter Nexavar.

Sprout resubmits its 'female Viagra' for FDA approval

Sprout Pharmaceuticals is heading back to the FDA with a twice-rejected treatment for female sexual dysfunction, betting that its follow-on studies will be enough to finally convince the agency.